SMT201500132B - Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate - Google Patents

Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate

Info

Publication number
SMT201500132B
SMT201500132B SM201500132T SM201500132T SMT201500132B SM T201500132 B SMT201500132 B SM T201500132B SM 201500132 T SM201500132 T SM 201500132T SM 201500132 T SM201500132 T SM 201500132T SM T201500132 B SMT201500132 B SM T201500132B
Authority
SM
San Marino
Prior art keywords
hepatitis
virus
bda
treatment
combination
Prior art date
Application number
SM201500132T
Other languages
English (en)
Italian (it)
Inventor
Nikolai Naoumov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201500132B publication Critical patent/SMT201500132B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SM201500132T 2011-04-01 2015-06-10 Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate SMT201500132B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470666P 2011-04-01 2011-04-01
PCT/EP2012/055857 WO2012131061A1 (en) 2011-04-01 2012-03-30 Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases

Publications (1)

Publication Number Publication Date
SMT201500132B true SMT201500132B (it) 2015-07-09

Family

ID=45952512

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500132T SMT201500132B (it) 2011-04-01 2015-06-10 Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate

Country Status (22)

Country Link
US (3) US20140011736A1 (xx)
EP (2) EP2694087B1 (xx)
JP (1) JP2014509630A (xx)
KR (1) KR20140010097A (xx)
CN (1) CN103458913A (xx)
AU (2) AU2012237295A1 (xx)
BR (1) BR112013024809A2 (xx)
CA (1) CA2831675A1 (xx)
CY (1) CY1116374T1 (xx)
DK (1) DK2694087T3 (xx)
ES (1) ES2533213T3 (xx)
HK (1) HK1193571A1 (xx)
HR (1) HRP20150430T1 (xx)
MX (1) MX2013011411A (xx)
PL (1) PL2694087T3 (xx)
PT (1) PT2694087E (xx)
RS (1) RS53911B1 (xx)
RU (1) RU2013148779A (xx)
SI (1) SI2694087T1 (xx)
SM (1) SMT201500132B (xx)
TW (1) TW201247216A (xx)
WO (1) WO2012131061A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208746A1 (en) * 2011-01-12 2012-08-16 Scynexis Inc. Genetic markers associated with response to cyclophilin-binding compounds
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
RU2662161C1 (ru) * 2017-08-11 2018-07-24 Васильевич Иващенко Александр Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита
JP2021534218A (ja) * 2018-08-23 2021-12-09 アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. インターフェロンラムダでのデルタ肝炎ウイルス感染処置
US20220313690A1 (en) * 2019-07-18 2022-10-06 Enyo Pharma Synergistic effect of eyp001 and ifn for the treatment of hbv infection
CN114945361A (zh) * 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
CN113662945A (zh) * 2020-05-15 2021-11-19 福建广生堂药业股份有限公司 用于治疗乙型肝炎的组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
EP0251575B2 (en) * 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (da) * 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
AU2005322242B2 (en) 2004-12-23 2010-02-11 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
BR112013024809A2 (pt) 2016-09-06
CN103458913A (zh) 2013-12-18
HK1193571A1 (en) 2014-09-26
EP3006037A1 (en) 2016-04-13
RU2013148779A (ru) 2015-05-10
US20160101146A1 (en) 2016-04-14
EP2694087B1 (en) 2015-01-28
ES2533213T3 (es) 2015-04-08
AU2016201888A1 (en) 2016-04-21
US20140011736A1 (en) 2014-01-09
MX2013011411A (es) 2014-04-14
HRP20150430T1 (hr) 2015-05-22
PT2694087E (pt) 2015-04-09
WO2012131061A1 (en) 2012-10-04
RS53911B1 (en) 2015-08-31
PL2694087T3 (pl) 2015-06-30
CY1116374T1 (el) 2017-02-08
SI2694087T1 (sl) 2015-05-29
AU2012237295A1 (en) 2013-09-19
KR20140010097A (ko) 2014-01-23
EP2694087A1 (en) 2014-02-12
US20150023917A1 (en) 2015-01-22
DK2694087T3 (en) 2015-04-13
JP2014509630A (ja) 2014-04-21
TW201247216A (en) 2012-12-01
CA2831675A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
SMT201500132B (it) Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
SMT201300043B (it) Inibitori del virus dell'epatite c
NZ702744A (en) D-amino acid compounds for liver disease
SMT201600470B (it) Inibitori del virus dell'epatite c
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
SMT201700029B (it) Inibitori del virus dell'epatite c
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
DK3495387T3 (da) Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
MX2012011222A (es) Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
CO6970603A2 (es) Composiciones y métodos para tratar el virus de la hepatitis c
EP2536425A4 (en) VACCINES FOR USE IN PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUS DISEASE
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
IL229902B (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
SMT201700028B (it) Composti benzofuranici per il trattamento delle infezioni da virus dell’epatite c
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BR112014007963A2 (pt) aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
HK1201262A1 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection (hcv)
BR112013024904A2 (pt) composto e método ex vivo de redução da infecciosidade ou de inativação de um vírus da hepatite c
IL225861A (en) Indazole-3-carboxamide derivatives and their use in the preparation of c-viral hepatitis drugs
BR112013008078A2 (pt) tratamentos de infecção por vírus da hepatite c
BR112013013166A2 (pt) tratamentos da infecção pelo vírus da hepatite c
PT2537528E (pt) As composições farmacêuticas contendo beta- e alfagalactosidase e a sua utilização no tratamento da doença do refluxo gastro esofágico